Rakesh Amin, MD
Psychiatry · Nashville, TNNPI 1437445475
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,176,991 of the $2,995,172 with a category attached, or 72.7%. It is spread thinly across 33 manufacturers, the largest accounting for just 18.5%. 2025 is the largest year on record at $878,924, 4.4 times the $201,104 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,293 payments — averaging $697.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$554K
- AbbVie$477K
- Alkermes, Inc.$461K
- Otsuka America Pharmaceutical, Inc.$320K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$320K
- Axsome Therapeutics, Inc.$303K
- plus $560K from 27 others
What the payments were for
- Consulting fees$233,3648%
- Speaking & faculty fees$2,176,99173%
- Travel & lodging$491,00816%
- Food & beverage$93,3783%
- Education$4310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,267,997
- ARISTADA$549,980
- INGREZZA$545,448
- VRAYLAR$470,421
- CAPLYTA$314,050
- Auvelity$297,923
- SPRAVATO$246,093
- REXULTI$219,340
- ARISTADA INITIO$128,906
- COBENFY$93,489
- ABILIFY MAINTENA$92,699
- AUSTEDO$73,620
- PERSERIS$38,925
- ABILIFY ASIMTUFII$36,287
- QELBREE$23,893
- UZEDY$12,519
- Dayvigo$7,936
- IGALMI$5,115
- Austedo XR$4,430
- NUPLAZID$586
How this compares
$2,995,172 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $833 |
| Quetiapine Fumarate | 11 | $138 |
| Trazodone Hcl | 14 | $119 |
| Alprazolam | 19 | $101 |
| Fluoxetine Hcl | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Nashville
- Robert JamiesonNashville$141K
- Michelle CochranNashville$74K
- Amanda Sparks-BushnellNashville$66K
- Craig ClarkNashville$31K
- Joseph SharpeNashville$29K
- Colleen FriddellNashville$23K
- Jane WeinbergNashville$22K
- Esiri EsinNashville$18K
- Tianlai TangNashville$11K
- Marianne RaynesNashville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.